These data provide evidence that therapeutic dosing of a TGF-β antagonist can diminish and potentially reverse hepatic fibrosis and also reduce the number and size of attendant cholangiocarcinomas. This evidence concerns the gene TGFB1 and cholangiocarcinoma.